JOURNAL ARTICLE

Findings from CEU Universities in Schizophrenia Reported (Randomised Controlled Trial of Clozapine In Resistant Schizophrenia and Schizoaffective Disorder).

  • Published In: Mental Health Weekly Digest, 2026. P. 1479 1 of 2

  • Database: Psychology Source 2 of 2

Abstract

This article focuses on a clinical trial conducted in Castellon de la Plana, Spain, evaluating the efficacy of clozapine (CLZ), an atypical antipsychotic, in treating treatment-resistant schizophrenia (TRS) and schizoaffective disorder (SZD). The prospective, three-month, evaluator-blinded study involving 127 participants found that CLZ significantly reduced psychotic and affective symptoms, with better outcomes observed in SZD patients compared to those with TRS. The research highlighted CLZ’s unique receptor profile and its positive impact on symptom scales and substance use in dual diagnosis cases. Funded by the Research Foundation of the Provincial Hospital of Castellon, the study supports CLZ’s clinical utility in complex psychiatric conditions. [Extracted from the article]

Additional Information

  • Source:Mental Health Weekly Digest. 2026/05, p1479
  • Document Type:Abstract
  • Subject Area:Health and Medicine
  • Publication Date:2026
  • ISSN:1543-6616
  • Accession Number:193781253
  • Copyright Statement:Copyright of Mental Health Weekly Digest is the property of NewsRx and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.